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Summary
Herein, we show that the hematopoietic-specific GEF VAV1 is ectopically expressed in primary pancreatic adenocarcinomas
due to demethylation of the gene promoter. Interestingly, VAV1-positive tumors had a worse survival rate compared to
VAV1-negative tumors. Surprisingly, even in the presence of oncogenic KRAS, VAV1 RNAi abrogates neoplastic cellular
proliferation in vitro and in vivo, thus identifying Vav1 as a growth-stimulatory protein in this disease. Vav1 acts synergistically
with the EGF receptor to stimulate pancreatic tumor cell proliferation. Mechanistically, the effects of Vav1 require its GEF
activity and the activation of Rac1, PAK1, andNF-B and involve cyclin D1 upregulation. Thus, the discovery of prooncogenic
pathways regulated by Vav1 makes it an attractive target for therapeutic intervention.
Introduction creasing evidence that signaling and transcriptional pathways
that control cell proliferation, differentiation, and apoptosis are
Pancreatic ductular adenocarcinoma is the most common pan- dysregulated in pancreatic cancer (Bardeesy and DePinho,
creatic tumor, accounting for more than 90% of all pancreatic 2002; Urrutia and DiMagno, 1997). Together, changes in these
cancers, and ranks fourth as a cause of death by cancer in the molecular pathways lead to abnormalities in growth factor-
United States (Jaffee et al., 2002). Pancreatic cancer has one mediated signaling cascades, cell cycle control, cellular migra-
of the poorest prognoses among human neoplasms, with an tion, and transcriptional regulation. In fact, gain-of-function
overall 5 year survival rate of 3%. This is due to the highly mutations in the KRAS protooncogene are among the most
aggressive and rapidly metastatic nature of the disease and the common genetic abnormality associated with pancreatic can-
fact that current diagnostic tools do not detect early stages of
cer, approaching a frequency of 95% (Hruban et al., 2001; Jaffee
the disease, as indicated by the reality that many patients have
et al., 2002). In addition, overexpression of EGF receptors andmetastases at the time of diagnosis. Besides surgical resection,
their ligands occurs frequently and is associated, like Kras, withwhich is only possible in a small fraction of patients (less than
the early developmental processes leading to pancreatic cancer20%) and which is rarely curative, current therapies for pancre-
development (Hruban et al., 2001; Korc, 1998). Lastly, antiprolif-atic cancer rely on traditional cytotoxic agents with limited ef-
erative pathways (e.g., TGF- andDPC4) and those that regulatefects throughout the course of the disease (Jaffee et al., 2002).
programmed cell death (e.g., TP53 and Akt) are frequently al-Therefore, efforts aimed at understanding themolecular mecha-
tered in pancreatic cancer (Jaffee et al., 2002). Despite thisnisms underlying the development of pancreatic cancer may
understanding of pancreatic cancer, therapies designed towardlead to prevention and treatment strategies that improve the
some of these pathways (e.g., Kras and EGFR) have remainedprognosis of the disease.
ineffective (Jaffee et al., 2002). Thus, the identification of addi-Although the underlying etiology and pathophysiology of
pancreatic ductal cancer are poorly understood, there is in- tional signaling pathways specifically upregulated in pancreatic
S I G N I F I C A N C E
Pancreatic cancer is the fourth leading cause of cancer death in the United States and remains virtually incurable. Despite significant
advances in our understanding of the molecular mechanisms contributing to the development of pancreatic cancer, current
therapies have remained ineffective; thus, new therapies rely on the identification of molecular targets that contribute to pancreatic
tumorigenesis. We have identified that VAV1 is misexpressed in 53% of pancreatic adenocarcinomas, is associated with decreased
survival, and contributes to the tumorigenic properties of pancreatic cancer cells. Interestingly, ablation of Vav1 in the presence of
oncogenic Kras abrogates neoplastic cell growth, suggesting a dependence on Vav1-regulated pathways for maintenance of the
transformed phenotype. Thus, Vav1-regulated pathways may serve as potential therapeutic targets in pancreatic cancer.
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cancer may provide novel functional targets for diagnosis, pre- Results and discussion
vention, and treatment of this deadly disease.
VAV1 is ectopically expressed in pancreatic cancerThe Rho family of GTP binding proteins function as molecu-
and associated with decreased survivallar switches going from an inactive GDP bound to an active
Using isoform-specific oligonucleotides and antibodies, weGTP bound state. When activated, these proteins interact with
screened normal human pancreas and eight human pancreatica variety of effectors to trigger distinct signaling pathways lead-
tumor cell lines for the expression of all three VAV isoforms.ing to reorganization of the actin cytoskeleton, proliferation,
Although VAV2 RNA and protein are present in all eight pancre-and antiapoptotic pathways. The role of Rho family proteins in
atic tumor cell lines and normal human pancreatic tissue (Sup-human tumorigenesis is becoming appreciated with the identi-
plemental Figures S1A and S1B at http://www.cancercell.org/fication of the overexpression and hyperactivation of some Rho
cgi/content/full/7/1/39/DC1/), we did not detect VAV3messageproteins in human cancers (Sahai and Marshall, 2002). Indeed,
in the normal human pancreas but did detect VAV3 RNA andnumerous cell surface receptors on pancreatic tumor cells, in-
protein in two of the eight cell lines (MiaPaCa2 and SU86.86;cluding those aberrantly expressed in the pancreatic tumor mi-
data not shown). Surprisingly, mRNA and protein of the hemato-croenvironment (e.g., IGF-I, EGF, PDGF) activate Rho family
poietic-specific VAV1 isoform were detected in three cell lines,
proteins (Matozaki et al., 2000; Sahai andMarshall, 2002). More-
CAPAN2, CFPAC, and MiaPaCa2, but not in normal human
over, Rho family proteins have been shown to be required for pancreas (Supplemental Figures S1A and S1B). Sequence anal-
ras-mediated transformation of 3T3 cells (Qiu et al., 1995a, ysis of VAV1 cDNA prepared from the VAV1-positive tumor cell
1995b); however, gain-of-function mutations in Rho family GTP lines shows that the Vav1 protein expressed in these cell lines
binding proteins, such as those found for ras, have not been is wild-type in nature (data not shown). Significantly, we did not
observed in human cancers. Thus, it has been speculated that observe the expression of VAV1 in multiple cell lines from four
dysregulation of the GDP-GTP cycle by either inhibition of other epithelial-derived tumor types, including breast, ovarian,
GTPase-activating proteins (GAPs) or expression of guanine lung, and colon. Interestingly, screening of tissue sections pre-
nucleotide exchange factors (GEFs), both of which would result pared frommouse pancreatic cancermodels reveals expression
in increased bound GTP, may participate in the hyperactivation of Vav1 in the elastase promoter-driven SV40 T-ag (Ela-Tg)
of Rho family signaling cascades in cancer (Bustelo, 2000; Sahai (Ornitz et al., 1987) and the preneoplastic lesions within the
and Marshall, 2002). Consistent with this idea, many GEFs, KRASG12D/pdx-Cre mouse (Hingorani et al., 2003), but not in the
including Dbl, Lbc, Lfc, Vav, Net, Ect2, and Tim, were originally normal tissue (Supplemental Figure S1C). In addition, themouse
isolated as oncogenes using in vitro 3T3 fibroblast transforma- overexpressing the dominant-negative TGF type II receptor
(DNR) using the mouse metallothionein I promoter, which dis-tion assays with DNA from various human tumors, but most
plays ductular hyperplasia (Bottinger et al., 1997), shows ex-were the result of oncogenic activation by truncation during the
pression of Vav1 (Supplemental Figure S1C). In order to deter-cloning procedure. Althoughbcr and larg are found as transloca-
mine if Vav1 protein expression is observed in primary humantion partners with abl and mll, respectively, the role of most Dbl
tumors, we screened paraffin-embedded tissue sections fromGEFs in regulating the tumorigenic properties of human cancers
15 normal and 95 pancreatic cancer patients for the expressionhas remained elusive.
of VAV1 using immunohistochemistry. Vav3 was not detectedThe Vav proteins (Vav1–Vav3) represent a novel family of
in either the normal pancreas or pancreatic adenocarcinomaDbl GEFs for Rho family GTPases that are regulated by tyrosine
specimens (data not shown). In contrast to VAV2 expression,phosphorylation downstream of several receptor and nonrecep-
which is observed in both the acinar and ductal epithelial cellstor tyrosine kinases (Bustelo, 2000; Turner and Billadeau, 2002).
in the normal pancreas and tumor specimens (SupplementalWhile VAV1 is primarily expressed in bone marrow-derived cell
Figure S2), VAV1 expression was not observed in either thelineages, where it has been extensively studied, VAV2 and VAV3
acinar or ductal epithelial cells in the normal pancreas sectionsdemonstrate a more ubiquitous pattern of gene expression.
but was present in greater than 50% of the tumor specimensInterestingly, although truncated versions of Vav proteins lack-
analyzed (Figure 1A). Importantly, the expression of VAV1 in the
ing the amino terminus have been found to transform 3T3 fibro-
VAV1 tumor specimens was specific to the epithelial tumor
blasts (Katzav et al., 1989; Movilla and Bustelo, 1999; Schuebel cells and did not stain the underlying stroma.
et al., 1996) and synergize with active Ras in transformation To determine the clinical significance of VAV1 ectopic ex-
(Bustelo et al., 1994; Katzav et al., 1995; Khosravi-Far et al., pression, patients with VAV1-negative and -positive tumors
1994), their role in human tumorigenesis has thus far not been were compared with respect to demographic (age, gender) and
described. The fact that pancreatic adenocarcinomas frequently prognostic (tumor size [cm] and stage [I–IV]) variables using chi-
overexpress growth factor receptor tyrosine kinases or their square tests for nominal variables and Wilcoxon rank sum tests
ligands (Korc, 1998) and harbor KRAS-activating mutations in for continuous and ordinal variables. Of the 95 patients analyzed
more than 95% of tumors suggested to us that Vav proteins for Vav1 protein expression, clinical data on 75 patients were
may participate in the pathogenesis of this disease. We found available. The mean age of the patients studied was 63.7 
thatVAV1 is expressed in an ectopicmanner in adenocarcinoma 11.3, and 57% of the patients were males. Of the patients in
of the pancreas and is associated with decreased survival in which staging was available, the mean size of the resected
pancreatic cancer patients. Furthermore, Vav1 contributes to lesion was 2.7 cm (1.09). By UICC staging, 11 (16%) were
the tumorigenic properties of pancreatic cancer cells by regulat- stage I, 15 (22%) were stage II, 37 (54%) were stage III, and 6
ing both cellular proliferation and cell survival pathways through (9%) were stage IV. Patients with VAV1-positive tumors were
the regulation of an EGF-Src-Vav1-Rac1-Pak1-NF-B-Cyclin less likely to be females (31% versus 69%); otherwise the two
groupswere comparable. The association between Vav1proteinD1 signaling axis.
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Figure 1. VAV1 is ectopically expressed in pancreatic adenocarcinoma
and associated with decreased survival
A: Immunohistochemical examination of normal human pancreas and pri-
Figure 2. Ectopic expression of VAV1 results from demethylation of theVAV1mary pancreatic cancers for the expression of VAV1. Paraffin-embedded
genetissue samples were prepared as described in the Experimental Procedures
and stained with normal rabbit serum (NRS) as a control or anti-Vav1 poly- A–I: Amplification of the VAV1 gene was assessed in the VAV1-expressing
clonal rabbit antisera. cell lines as well as in the primary pancreatic adenocarcinomas analyzed
B: Kaplan-Meier survival curve of VAV1 and VAV1 patients. by fluorescent in situ hybridization. The VAV1 gene maps to chromosome
19p13; a telomere probe to chromosome 19 is shown in green, and the
VAV1 genomic probe is shown in red. A normal metaphase spread demon-
strates the localization of the two probes (A). The tumor cells lines are
CAPAN2 (B), CFPAC (C), BXPC3 (D), PANC1 (E), ASPC1 (F), and three primary
status and survival was assessed with Kaplan-Meier curves and pancreatic cancers (G–I).
a log rank test. On univariate analysis, VAV1-negative tumors J: DNA from the indicated pancreatic tumor cell lines and primary pancre-
atic cancer specimens was left untreated or was treated with sodium bisul-had a better survival compared to VAV1-positive tumors (p 
fite in order to determine the methylation status of the VAV1 gene by0.018) (Figure 1B). Vav1 protein status was the only significant
methylation-specific PCR (MSP). Following the treatment, the DNA was puri-factor predicting survival (p  0.03) on multivariate analysis,
fied and subject to MSP as described in the Experimental Procedures. The
after adjusting for gender, tumor size, and stage. Thus, these methylation-specific products were resolved on 2.5% agarose gels and visu-
data suggest that VAV1misexpression may lead to a decreased alized following staining with ethidium bromide. DNA from theVAV1-express-
ing Jurkat T cell line was used as a control for MSP.survival benefit in pancreatic cancer patients.
K: The indicated tumor cell lines were left untreated or were treated with
5AZAdc/TSA for 4 days, and RNA was subsequently extracted. VAV1 andEctopic expression of VAV1 is due to demethylation GAPDHgene expression was analyzed by RT-PCR as described in the Experi-
of the VAV1 gene promoter mental Procedures.
In order to investigate the mechanism for dysregulated expres-
sion of VAV1, we performed fluorescence in situ hybridization
(FISH) analysis on VAV1-expressing and nonexpressing pancre-
atic tumor cell lines. We found that the VAV1 cell lines each of paraffin-embedded tumor samples has revealed no amplifi-
cation of the VAV1 gene (Figures 2G–2I). This suggested to uscontained 2 copies of the VAV1 gene, as did ASPC1, a cell line
that does not express VAV1 (Figures 2B, 2C, and 2F). However, that gene amplification was not the mechanism by which the
VAV1 gene was being aberrantly expressed in the two VAV1BXPC3 and PANC1, two VAV1 cell lines, contained 3 copies
of the VAV1 gene (Figures 2D and 2E). Moreover, FISH analysis tumor cell lines and pancreatic cancer tissues.
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Since epigenetic abnormalities leading to the activation of
oncogenes or inactivation of tumor suppressors play a key role
in tumorigenesis, we sought to determine if epigenetic changes
in the VAV1 gene contributed to aberrant gene expression. We
first analyzed the methylation status of the VAV1 gene using
methylation-specific PCR (MSP). Following bisulfite treatment
of the DNA, MSP amplification of the VAV1 gene was not de-
tected in the cell lines that express VAV1 as well as in treated
DNA from primary human pancreatic tumors (Figure 2J) but was
detected in the VAV1 PANC1 cell line (Figure 2J), indicating
that the VAV1 gene is not appropriately methylated in VAV1-
expressing cell lines and pancreatic tumor specimens. Interest-
ingly, all cell lines, regardless of VAV1 status, were able to
activate a luciferase gene under the control of the VAV1 pro-
moter (Denkinger et al., 2000) (data not shown), suggesting that
transcriptional activators of this gene are present in these cells.
We next tested whether treatment with the DNA demethylation
agents 5Aza-dC and TSA would lead to the expression of VAV1
in nonexpressing pancreatic tumor cell lines. In fact, the VAV1
PANC1 and CAPAN1 cell lines express VAV1 upon 5Aza-dC
and TSA treatment (Figure 2K), indicating that demethylation
of the VAV1 gene can result in expression in these cell lines.
Thus, the ectopic expression of VAV1 in primary pancreatic
cancer is the result of an epigenetic modification of the VAV1
gene. Figure 3. Vav1 ablation leads to reduced tumorigenic properties in vitro
and in vivo
VAV1 is required for anchorage-independent growth A: The VAV1-expressing cell lines CFPAC and MiaPaCa2 were transfected
with a GFP-expressing plasmid and either a control vector (pSSH1P), a short-and tumor formation in vivo
hairpin (sh) RNA vector that targets the Vav1 mRNA (shVav1-1), or a mutantThe misexpression of VAV1 prompted us to examine its signifi-
Vav1-targeting construct (shVav1mt). One day posttransfection, the cells
cance in the tumorigenic properties of pancreatic tumor cells. were sorted for GFP expression, and then 2  104 cells were plated in
To this end, we generated short hairpin RNA-targeting vectors quadruplicate as described in the Experimental Procedures. Two weeks
later, the number of visible colonies was scored.toward VAV1 (shVav1-1 and shVav1-2) in order to acutely si-
B: MiaPaCa2 cells were transfected with the indicated plasmids, and an-lence this gene product and thenmeasured cellular proliferation.
chorage-independent growth was analyzed. The inset shows suppressionImportantly, the shVav1-1 and shVav1-2 targeting vectors de- of Vav1 and reexpression of Vav1r in MiaPaCa2 cells.
plete Vav1 protein levels in all three VAV1 tumor cell lines and C–E: CAPAN2 and CFPAC (D) cells were transfected with the indicated
constructs and injected in the flank of male athymic nude mice (n  9 fordo not affect the ubiquitously expressed VAV2 (Supplemental
each experimental condition). Weekly measurements were taken from theFigure S3 at http://www.cancercell.org/cgi/content/full/7/1/39/
tumors, and the mean tumor volume was determined after 6 weeks. E: ADC1/). Using the RNA interference vectors toward VAV1, we representative example of tumor mass is shown for the CAPAN2 cell line
determined the ability of VAV1CFPAC andMiaPaCa2 pancre- transfected with either the shVav1mt or shVav1-1 targeting construct. Ex-
pression of the angiogenic marker CD34 was determined by immunohisto-atic tumor cells to form colonies in soft agar. Suppression of
chemical analysis of CAPAN2 tumors.Vav1 in the oncogenic KRAS-containing CFPAC and MiaPaCa2
cell lines results in a substantial reduction in colony formation
in soft agar compared to the control-transfected populations
(Figure 3A). Importantly, cotransfection of a shRNA-resistant in vivo and in vitro, even in the presence of oncogenic alleles
Vav1 cDNA (Vav1r) could completely reverse the anchorage- of KRAS.
independent growth characteristics observed in Vav1-depleted
MiaPaCa2 cells (Figure 3B). In order to further examine the VAV1 regulates cellular proliferation and survival
affect of Vav1 suppression on pancreatic tumorigenesis, we pathways in pancreatic cancer cells
injected Vav1-suppressed or control-transfected cells subcuta- The data above indicate that VAV1 participates in the tumori-
neously into the flank of irradiated male athymic nude mice and genic properties of pancreatic tumor cells. However, whether
monitored the increase in tumor volume over a 6 week period. depletion of Vav1 was affecting tumor cell proliferation or cell
Significantly, suppression of Vav1 in theCAPAN2 cell line results survival was unclear.We therefore examined these two possibil-
in a dramatic reduction in tumor volume (Figures 3C and 3E), ities. Using the Vav1 shRNA vectors, we analyzed cellular prolif-
whereas the CFPAC cell line shows a less dramatic, yet repro- eration. Depletion of Vav1 in all of the VAV1 tumor cell lines
ducible reduction in tumor volume (Figure 3D). Consistent with results in a pronounced decrease in cellular proliferation as
the effect of Vav1 in tumor formation, we observe a decrease measured by either BrdU incorporation (Figure 4A) orMTS assay
in expression of the angiogenic marker CD34 (Figure 3E), thus (Supplemental Figures S4A–S4C at http://www.cancercell.org/
supporting the notion that VAV1 participates in the tumorigenic cgi/content/full/7/1/39/DC1/). A similar effect on cellular prolifer-
properties of pancreatic cancer cells. These data indicate that ation was observed using the shVav1-2 targeting vector (Sup-
plemental Figure S4D). Similarly, a decrease in proliferation asVAV1 is required for maintenance of the transformed phenotype
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interesting in light of the fact that all three VAV1 tumor lines
contain activating alleles of KRAS, a gene that is frequently
altered in pancreatic cancer and that is associated with the
early progression of the disease. Although we do not know
at which stage in the development of adenocarcinoma of the
pancreas VAV1 is being misexpressed, it has been previously
noted that Ras and Vav can synergize in the transformation of
3T3 cells and that dominant-negative Ras could block the ability
of oncogenic Vav to promote the transformation of 3T3 cells
(Katzav et al., 1995). Indeed, Vav1 acts synergistically with Kras
to stimulate pancreatic tumor cell proliferation (data not shown).
Moreover, a dominant-negative version of Vav1 lacking a func-
tional SH2 domain has been observed to not only block transfor-
mation of oncogenic Vav, but also inhibit transformation induced
by oncogenic Ras (Katzav et al., 1995). Therefore, it is possible
that the misexpressed VAV1 becomes an integral part of the
proliferative signaling pathways in the developing cancer and
that subsequent removal of Vav1 protein has detrimental effects
on the growth characteristics of pancreatic tumor cells.
Vav1 target molecules have been found to be involved in
cell survival (Murga et al., 2002). Since the decrease in cellular
proliferation could be the result of increased apoptosis, we
examined whether depletion of Vav1 altered cell survival in pan-
creatic tumor cells. In fact, as shown in Figure 4B, removal of
Vav1 led to an increase in apoptosis of the VAV1 tumor cell
lines but had no effect on the VAV1 tumor cell lines. This
phenotype could also be reversed by coexpression of the Vav1r
cDNA (Figure 4D). Similarly, an increase in apoptosis was ob-
served in xenograft CAPAN2 tumors in which Vav1 had been
Figure 4. VAV1 is required for pancreatic tumor cell proliferation and survival suppressed using RNAi (Figure 4E). Thus, VAV1 in pancreatic
A: The VAV1 CAPAN2, CFPAC, and MiaPaCa2 pancreatic tumor cell lines cancer participates in both cellular proliferation and cell survival
were transfected with a GFP-expressing vector and the indicated shRNA pathways, both of which contribute to the tumorigenic proper-
vectors. BrdU incorporation at 72 hr posttransfection was performed as ties of pancreatic tumor cells.described in the Experimental Procedures.
VAV2, like VAV1, is oncogenic in a 3T3 transformation assayB: The indicated cell lines were transfected with GFP and the shVav1mt or
and can couple to multiple nonreceptor and receptor tyrosineshVav1-1 targeting construct. GFP positive cells were scored for apoptotic
nuclei using the DNA stain Hoechst 33860. kinases (Schuebel et al., 1996, 1998). It was therefore surprising
C: MiaPaCa2 and CFPAC cells were transfected with the indicated plas- that depletion of Vav1 or inhibition of Vav1 using a dominant-
mids, and BrdU incorporation was measured as described in A.
negative construct would alter the proliferative properties ofD: MiaPaCa2 and CAPAN2 cells were transfected with the indicated plas-
pancreatic tumor cells, since the closely related isoform VAV2mids and apoptosis was measured as described in B.
E: Cellular proliferation and apoptosis in CAPAN2 tumors were analyzed by is present in all of the cell lines. Although the role of VAV2 in
PCNA immunodetection and TUNEL assay, respectively. tumor cell proliferation or cell survival has not been determined,
the fact that these two family members have the capacity to
regulate an overlapping set of Rho family GTPases indicated
that these two isoforms may be differentially contributing to the
measured by the expression of the proliferation marker PCNA phenotype of pancreatic cancer cells. Since VAV2 is expressed
was observed in xenograft CAPAN2 tumors in which VAV1 had in all cell lines and primary pancreatic tumors, we wanted to
been suppressed using RNAi (Figure 4E). Importantly, transfec- assess whether, like VAV1, VAV2 would be necessary for tumor
tion of neither shVav1-1 nor shVav1-2 affected the proliferation cell proliferation. To determine if VAV2 participates in cellular
of the VAV1 tumor cell lines PANC1, BXPC3, or ASPC1 (Sup- proliferation of pancreatic cancer cells, we generated a VAV2
plemental Figure S5A). Taken together, these data suggest that shRNA vector and determined if suppression of Vav2 protein
Vav1 contributes to the proliferative capacity of pancreatic tu- levels led to a similar decrease in cellular proliferation in either
mor cells. Furthermore, reintroduction of a Vav1-resistant cDNA VAV1 or VAV1 tumor cell lines (Supplemental Figures S5C
(Vav1r) into any of the shVav1-1-treated Vav1 tumor cells and S5D at http://www.cancercell.org/cgi/content/full/7/1/39/
rescued the Vav1-suppressed proliferation phenotype (Figure DC1/). In contrast to what was observed for Vav1, depletion of
4C). Similarly, a dominant-negative Vav1 protein (amino acids Vav2 protein did not affect cellular proliferation of any pancreatic
1–189; Vav1DN) that is predicted to inhibit Vav1 GEF activity tumor cell lines examined (Supplemental Figure S5D). Thus,
(Abe et al., 1999; Aghazadeh et al., 2000; Movilla and Bustelo, although these two family members share a significant degree
1999) and T cell activation (data not shown) results in a decrease of homology at the amino acid and structural level, as well as
in proliferation of the VAV1 CAPAN2 and CFPAC tumor cells, the ability to regulate an overlapping set of Rho family GTP
but not the proliferation of the VAV1 PANC1 and BXPC3 cell binding proteins, only VAV1 is contributing to the growth-pro-
moting pathways in pancreatic cancer cells. Indeed, Vav2 pro-lines (Supplemental Figure S5B and data not shown). This is
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tein is present in hematopoietic cells but, unlike Vav1, does not
participate in the development of the T cell lineage (Turner et
al., 1997) but does play a partially redundant role with VAV1 in
B cell development (Doody et al., 2001). Moreover, although
the GEF activity of Vav1 and Vav2 are regulated by tyrosine
phosphorylation, truncation of the first 65 amino acids of Vav1
results in increased GEF activity and 3T3 transformation,
whereas the removal of the entire first 180 amino acids is re-
quired to activate the GEF activity of Vav2 and unleash its trans-
forming potential. Thus, whether the mechanism of GEF regula-
tion is involved in the difference observed between these two
family members remains to be determined. Lastly, whether
VAV2 is involved in some other aspect of pancreatic tumor
cell biology remains to be determined. In fact, VAV2 has been
suggested to participate in cell-cell adhesion through its interac-
tion with E-cadherin binding protein p120Catenin (Fukata and
Kaibuchi, 2001; Noren et al., 2001). Thus, it remains possible
that VAV2 may be involved in the migratory and metastatic
potential of pancreatic tumor cells.
Vav1 requires its GEF activity to promote pancreatic
cancer cell proliferation
To investigate the functional significance of VAV1 expression
in pancreatic cancer, we assessed the effect of Vav1 protein
expression on the proliferative potential of VAV1 pancreatic
tumor cell lines. Compared to control-transfected cells, expres-
sion of Vav1 protein in the KRAS mutant PANC1, ASPC1, or
KRAS wild-type BXPC3 cell line resulted in increased prolifera-
tion as measured by BrdU incorporation and MTS assay (Figure
5A and data not shown), thus indicating that ectopic expression
of VAV1 is increasing their proliferative capacity.We next sought
to determine if the increased proliferation of pancreatic tumor
cells by Vav1 requires GEF activity; we expressed a Vav1 protein
lacking GEF function in the PANC1 cell line to determine if the
Figure 5. Characterization of the Vav1-mediated cellular proliferation path-activation of Rho GTP binding proteins was required for Vav1-
way in pancreatic cancer cells
mediated proliferation of pancreatic tumor cell lines. Indeed,
A: The PANC1 cell line was transfected, with either wild-type Vav1 or hyper-
the GEF activity was required (Figure 5A and Supplemental active mutants of Vav1 (Vav1 CH, Vav1 3YF), and cellular proliferation
Figure S6A at http://www.cancercell.org/cgi/content/full/7/1/ was measured as described above.
B: BXPC3 cells were transfected with Vav1 expression plasmid, and BrdU39/DC1/). Taken together, these data suggest that GEF activity
incorporation was measured in the absence (NIL) or presence of EGF (200is required for Vav1-mediated proliferative responses in pancre-
ng/ml) stimulation as described above. Vav1 was immunoprecipitated fromatic tumor cells.
serum-starved CAPAN2 and CFPAC cells pre- or post-EGF stimulation for 5
We next tested whether the expression of known oncogenic min (top left) or in CAPAN2 over the indicated time course (bottom left).
versions of VAV1 can further promote tumor cell proliferation. Bound proteins were resolved by SDS-PAGE and immunoblotted using the
indicated antibodies.Interestingly, the expression of either an oncogenic truncation
C:CAPAN2 cells were serum starved and then pretreated with the indicatedmutant lacking the CH domain (Vav1CH) or a mutant con-
inhibitors for 1 hr and then stimulated for 5 min with EGF (100 ng/ml). Vav1
taining tyrosine to phenylalanine changes at all three residues proteins were immunoprecipitated, and bound proteins were resolved by
within the acidic region (Vav1 3YF) did not further increase SDS-PAGE and immunoblotted using the indicated antibodies.
D: CAPAN2 cells were cotransfected with either a control or Vav1 or Vav2cellular proliferation compared to that observed by overexpres-
suppression vector and expression vectors for the indicated FLAG-taggedsion of wild-type VAV1 (Figure 5A). Thus, these data indicate
Rho family GTPases. Forty-eight hours posttransfection, cell lysates werethat the overexpression of VAV1 in these epithelial tumor cell
prepared, and GTP-loaded Rac1, Cdc42, and RhoA were pulled down
lines is sufficient in driving the cell proliferation. This is interest- using GST-Pak(PBD), GST-WASp(CRIB), and GST-Rhotekin(RBD), respectively.
ing in light of the fact that wild-type Vav1 is far less transforming Bound proteins were detected by anti-FLAG immunoblotting. Total cell ly-
sates (100 	g) were also loaded for expression control of the FLAG epitope-in the in vitro 3T3 transformation assay than either the truncation
tagged Rho family GTPases.or 3YF mutant (Katzav et al., 1991; Lopez-Lago et al., 2000;
E: CAPAN2 cells were transfected with either a control or Vav1 suppression
Zugaza et al., 2002). However, it is possible that Vav1 can vector and the pRaichu-Rac1 FRET construct. Forty-eight hours posttransfec-
synergize with other molecular pathways that are altered in tion, fluorescence was measured over time (90 s, unstimulated) using a
fluorescence plate reader as described in the Experimental Procedures.these pancreatic cancer cell lines in order to promote tumor cell
F: CAPAN2 cells were transfected with either a control or Vav1 suppressionproliferation. Moreover, since neither truncation nor mutational
vector, and 48 hr posttransfection cells were stimulated with 100 ng/ml EGF.
activation of VAV1 is found in the VAV1 tumor cell lines (Sup- Cell lysates were prepared, and 100 	g of protein was resolved by SDS-
plemental Figure S1B at http://www.cancercell.org/cgi/content/ PAGE and probed with the indicated antibodies.
full/7/1/39/DC1/ and data not shown), such mutations may not
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Figure 6. Vav1 increases the expression of cyclin
D1 by regulating its promoter activity
A: PANC1 cell lines transfected with Vav1 display
an increase in the expression of Cyclin D1 as
shown by gene array analysis (top) and RNase
protection assay (bottom).
B: Western blot analysis for cyclin D1 levels in
whole-cell lysates from PANC1 cells transfected
with Vav1 or control vector (left) and densitome-
try (right).
C: The level of expression of cyclin D1 was deter-
mined by immunohistochemistry in CAPAN2 tu-
mors (left) and two Vav1 and two Vav1 pan-
creatic cancer tissues (right).
D: PANC1 cells were transfected with a cyclin
D1 promoter-luciferase reporter construct and
either a control vector, Vav1, or the GEF-defi-
cient Vav1 expression vector. Luciferase activity
was measured 2 days posttransfection as de-
scribed in the Experimental Procedures. Control
Western blot shows expression of the Vav1 wild-
type and mutant.
E:PANC1 cells were transfected with control vec-
tor or Vav1 expression vector and NF-B lucifer-
ase reporter construct (left). CAPAN2 cells were
transfected with a control or Vav1 suppression
vector and NF-B luciferase reporter construct
(right). Luciferase activity was measured as de-
scribed above.
F: PANC1 cells were transfected with a control
or Vav1 expression vector and chromatin immu-
noprecipitation assay was performed as de-
scribed in the Experimental Procedures.
be required to activate Vav1 GEF activity in these tumors. In cell lines is similar to that of the oncogenic versions (data not
shown).fact, the GEF activity of Vav1 may be modulated by growth
factor-induced tyrosine phosphorylation, since aberrant growth
factor receptor expression and autocrine/paracrine production Vav1 regulates the activation of a Rac1-Pak1 pathway
of ligands occur frequently in human tumors and, in particular, in an EGF-stimulated manner
in pancreatic cancer (Korc, 1998). Indeed, we have found that Aberrant expression of both growth factor receptors and growth
Vav1 from serum-starved (48 hr) CAPAN2 and CFPAC cell lines factors is commonduring pancreatic cancer cell evolution (Korc,
is still tyrosine phosphorylated (Figure 5B). Although stimulation 1998). Indeed, Vav1 becomes rapidly tyrosine phosphorylated
of serum-starved CAPAN2 cells with EGF leads to an increase in following the addition of EGF, insulin, or IGF (Figure 5B and
the tyrosine phosphorylation of Vav1, we are unable to observe data not shown). Significantly, the addition of EGF to VAV1-
changes in the level of tyrosine phosphorylation of Vav1 from expressing cells results in increased cellular proliferation (Figure
5B). To determine if Vav1 phosphorylation through the EGFCFPAC cell in response to EGF because of the high basal level
of phosphorylation (Figure 5B). Thus, it is possible that the receptor requires Src or binding to tyrosine phosphorylated EGF
receptor, we analyzed EGF-stimulated tyrosine phosphorylationhigh levels of basal tyrosine phosphorylation observed in these
cancer cells led to constitutive activation of Vav1. In fact, the of Vav1 from serum-starved CAPAN2 cells. As shown in Figure
5C, Vav1 underwent EGF-stimulated tyrosine phosphorylationGEF activity of endogenous Vav1 from CAPAN2 and CFPAC
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that was blocked by pretreatment of cells with either the Src
kinase inhibitor PP2 or the EGFR inhibitor PD153035. These
data suggest that tyrosine phosphorylation of Vav1 downstream
of the EGFR in pancreatic cancer cells requires both Src and
the EGFR.
The results described above suggest that Vav1 GEF activity
is required for its ability to promote pancreatic cancer cell prolif-
eration. Therefore, we asked which Rho GTPase family member
was most affected by depletion of Vav1. Previous studies have
indicated that Vav1 can act as a GEF for Rac1, Cdc42, and
RhoA (Schuebel et al., 1998; Movilla and Bustelo, 1999; Abe et
al., 2000; Movilla et al., 2001). As shown in Figure 5D, removal
of Vav1 in the CAPAN2 cell line led to a decrease in the basal
levels of Rac1-GTP but did not affect levels of GTP bound
Cdc42 or RhoA. Densitometric analysis reveals a greater than
50% decrease in GTP bound Rac1; shVav1mt (100%) versus
shVav1-1 (40%) versus shVav2-1 (82%), whereas GTP bound
Cdc42; shVav1mt (100%) versus shVav1-1 (94%) versus
shVav2-1 (91%) andGTPboundRhoA; shVav1mt (100%) versus
shVav1-1 (104%) versus shVav2-1 (93%) remained largely un-
changed. To determine if Vav1 regulates the levels of Rac1-
GTP following EGF stimulation, we made use of a previously
described Rac1 fluorescence resonance energy transfer (FRET)
biosensor that can quantitatively measure Rac1 GTP binding
(Itoh et al., 2002). Significantly, whereas VAV1 CAPAN2 cells
show an increase in FRET upon addition of EGF, Vav1-sup-
pressed CAPAN2 cells fail to stimulate Rac1-GTP binding fol-
lowing EGF stimulation (Figure 5E). Moreover, consistent with
the GST pull-down data shown in Figure 5D, we did not observe
significant differences in the ability of Vav1-suppressed cells to
regulate Cdc42 and RhoA FRET biosensors in the absence
or presence of EGF stimulation (data not shown). We further
characterized the downstream signaling pathways regulated by
Vav1 using phospho-specific antibodies toward Rac1 target
molecules. As shown in Figure 5F, depletion of Vav1 in the Figure 7. Vav1-mediated activation of the cyclin D1 promoter requires an
CAPAN2 cell line results in a defect in the basal and EGF- intact EGF-Src-Vav1-Rac1-Pak1-NF-B signaling pathway in pancreatic can-
stimulated activation of the Rac1 effector molecule Pak1. In cer cells
addition, we observed a decrease in EGF-stimulated JNK acti- A–C: BXPC3 (A) and CAPAN2 (B and C) cells were transfected with the
indicated vectors, and cyclin D1 promoter activity was measured in thevation in the absence of Vav1, aswell as a small but reproducible
absence (NIL) or presence of EGF (200 ng/ml). In A and B, cells were treateddecrease in ERK activation (Supplemental Figure S6 at http://
with 50 nm PD153035 (A) or 100 nm PP2 (B). CAPAN2 (C), MiaPaCa2 (E),www.cancercell.org/cgi/content/full/7/1/39/DC1/). Taken together, and PANC1 (C, D, and F) cells were transfected with the indicated vectors,
these data identify Vav1 as an Src target downstream of the and cyclin D1 promoter activity was measured as described above.
EGFR and reveal a role for Vav1 in the regulation of an EGF-
stimulated Rac1-Pak1 pathway in pancreatic cancer cells.
Cyclin D1 is a molecular target of VAV1 of Vav1 in PANC1 augmented cyclin D1 promoter activity in a
in pancreatic tumor cells GEF-dependent manner (Figure 6D). In addition, expression of
To identify downstream molecular targets of Vav1 that are in- Vav1 in both ASPC1 and BXPC3 led to an increase in cyclin
volved in cell proliferation, we performed expression array and D1 promoter activity (data not shown). Taken together, these
RNase protection assays for genes whose protein products are data indicate that Vav1 can promote tumor cell proliferation in
involved in regulating cellular proliferation. As determined by part through the upregulation of cyclin D1.
both methods, mRNA levels of cyclin D1 were significantly in- Vav1 has been shown in several cell systems to modulate
creased over the control-transfected population (Figure 6A), gene expression through the regulation of several transcription
and this correlated with increased cyclin D1 levels in Vav1- factors, including AP-1, NFAT, and NF-B. Indeed, overexpres-
transfected cells (Figure 6B). Similarly, VAV1-positive CAPAN2 sion of Vav1 stimulates increased activity of luciferase reporter
tumors show increased level of cyclin D1 compared to CAPAN2 constructs containing binding sites for these individual tran-
tumors where Vav1 was suppressed using RNAi (Figure 6C). scription factors (Figure 6E and data not shown). Consistent
Furthermore, pancreatic cancer tissues that were negative for with the role of Pak1 in the activation of NF-B, we find that
VAV1 demonstrate lower cyclin D1 levels compared to VAV1- kinase-dead Pak1 can inhibit basal as well as Vav1-mediated
positive specimens (Figure 6C). Consistent with a role for Vav1 activation of NF-B in pancreatic cancer cells (data not shown).
Significantly, depletion of Vav1 by RNAi in CAPAN2 cells resultsGEF activity in pancreatic cancer cell proliferation, expression
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in decreased activation of the isolated NF-B reporter (Figure Our results uncover a novel role for the hematopoietic-spe-
6E). Furthermore, chromatin immunoprecipitation from cells ex- cific Rho GEF VAV1 in the regulation of a prooncogenic pathway
pressing Vav1 demonstrates NF-B binding to the cyclin D1 in pancreatic tumor cells and demonstrate synergistic effects
promoter compared to control cells (Figure 6F), suggesting a between this protein and recently established drug targets for
role for this transcription factor in the Vav1-mediated regulation this disease such as Kras and the EGFR (Wolff, 2001). In addi-
of cyclin D1 gene expression in pancreatic cancer cells. tion, our data would suggest that Pak1 and Src inhibitors could
show clinical benefit in the treatment of pancreatic cancer.
Inhibition of Vav1 downstream targets abrogates Therefore, increased knowledge of the mechanisms and signal-
cyclin D1 promoter activity ing pathways controlled by Vav1 in this disease may provide
Recent data have demonstrated that there is a correlation be- the theoretical framework for the development of novel small
tween EGF, EGFR, and cyclin D1 levels in pancreatic cancer molecule inhibitors to combat this deadly disease.
(Poch et al., 2001). Since Vav1 is a target of the EGFR and Vav1
Experimental proceduresundergoes receptor-mediated tyrosine phosphorylation, we in-
vestigated whether EGF could potentiate Vav1-mediated cyclin
ReagentsD1 promoter activity. As shown in Figure 7A, addition of EGF
Unless otherwise specified, all reagents were from Sigma (St. Louis, MO).to Vav1-transfected cells potently augments cyclin D1 promoter
Rabbit polyclonal antisera toward Vav1, Vav2, andVav3 have been previously
activity. Consistent with the role of tyrosine phosphorylation described (Billadeau et al., 2000a, 2000b; Cao et al., 2002). Antisera for
regulating Vav1 activity, treatment of CAPAN2 cells with either phospho-specific and total protein levels of Pak1 (T199/204), JNK, and
PP2 or PD153035 abrogated basal and EGF-stimulated cyclin ERK1/2 were obtained from Cell Signaling Technology Inc. (Beverly, MA).
Antibodies for CD34 were obtained from Becton Dickinson, p65 was ob-D1 promoter activity (Figures 7B and 7C). We next investigated
tained from Santa Cruz, and PCNA was obtained from BD Bioscience.if the downstream targets of Vav1were required in the regulation
of cyclin D1 promoter activity. Consistent with the notion that
ImmunohistochemistryVav1 is regulating Rac1 in pancreatic cancer cells, suppression
Institutional review board approval was obtained for all studies involvingof Rac1 in CAPAN2 cells leads to decreased cyclin D1 promoter
human specimens. Immunohistochemistry was carried out on paraffin-
activity similar to what was observed using a dominant-negative embedded normal and pancreatic cancer specimens using ZymedHistostain
mutant of Rac1 (Figure 7C). Similarly, the kinase-dead Pak1 Plus as per manufacturer’s protocol and is described in the Supplemental
was able to block basal cyclin D1 promoter activity in the Data at http://www.cancercell.org/cgi/content/full/7/1/39/DC1/.
CAPAN2 cell line (data not shown). Furthermore, kinase-dead
FISH, methylation-specific PCR, and 5-Aza TSAPak1 was also capable of abrogating Vav1 stimulation of the
Details of these techniques are described in the Supplemental Data at http://cyclin D1 promoter in PANC1 cells (Figure 7D). Furthermore,
www.cancercell.org/cgi/content/full/7/1/39/DC1/.abrogation of NF-B activation by expression of the dominant-
negative IB
S/A leads to a significant inhibition of cyclin D1
Tumor xenografts
promoter activity in the MiaPaCa2 (Figure 7E) and PANC1 (Fig-
We injected 2.5 106 CAPAN2 and CFPAC pancreatic cells subcutaneously
ure 7F) cell lines. Taken together, these data identify a receptor- into the hind leg of a male athymic nude mice and measured the tumor
mediated Vav1 signaling pathway in pancreatic cancer cells in weekly. We estimated tumor volume (V ) from the length (l ) and width (w ) of
which EGF stimulation leads to the tyrosine phosphorylation of the tumor using the formula: V  (/6)  [(l  w )/2]3. Animal experiments
were carried out using protocols approved by the Animal Facility at MayoVav1 in a Src-dependent manner, followed by the activation of a
Clinic College of Medicine.Rac1-Pak1-NF-Bsignaling cascadedriving cyclinD1 promoter
activity.
Proliferation and apoptosis assaysUnderstanding the etiology of pancreatic cancer is of para-
These assays are described in detail in the Supplemental Data at http://mount importance, as it will contribute to our understanding
www.cancercell.org/cgi/content/full/7/1/39/DC1/.
of the molecular pathways that control pancreatic tumor cell
proliferation and metastasis. Herein, we have shown ectopic Immunoprecipitation and Western blotting
expression of the hematopoietic-specific protein Vav1 in a can- Details regarding these methods are described in the Supplemental Data at
cer of epithelial origin. Significantly, we find that pancreatic http://www.cancercell.org/cgi/content/full/7/1/39/DC1/.
cancer patients with VAV1-expressing tumors have a decrease
Soft agar growth assayin survival. Moreover, our data indicate that VAV1 not only im-
CFPAC or MiaPaca2 cells (1  107) were cotransfected with a GFP expres-parts a proliferative advantage to pancreatic tumor cells, but
sion vector (100 ng) and either the control pFRT-H1P, Vav1, or Vav1mtalso plays a transforming role, similar to that ofKRAS (Brummel-
targeting vector as described above. In rescue experiments, a resistant
kamp et al., 2002). In addition, Vav1, Kras, and EGFR signaling version of the human Vav1 cDNA was also transfected (10 	g). Eighteen
pathways can synergize to promote pancreatic tumor cell prolif- hours posttransfection GFP cells were sorted by FACS and 2  104 GFP
eration. The data herein suggest that VAV1 participates in pan- cells were mixed with 4 ml of RPMI medium containing 10% serum and
creatic tumorigenesis and can regulate cellular proliferation 0.4% low melting point (LMP) agarose. One milliliter of this mixture was
subsequently placed over 1 ml of hardened RPMI medium containing 10%through the activation of a Vav1-Rac1-Pak1-NF-B axis that
BCS and 1% LMP and allowed to harden at room temperature. The cellsleads to the increase in cyclin D1 and thus increased pancreatic
were allowed to grow for 2 weeks, after which visible colonies containingtumor cell proliferation. The recent observation of VAV1 expres-
greater than 50 cells were counted.sion in neuroblastomas suggests that VAV1 may participate in
human tumorigenesis in sites other than the pancreas (Betz et RNase protection assay and expression array
al., 2003; Hornstein et al., 2003). Whether VAV1 is involved in Experimental procedures for the RNase protection assay and Genearray are
the tumorigenic properties of this tumor type will require further described in detail in the Supplemental Data at http://www.cancercell.org/
cgi/content/full/7/1/39/DC1/.investigation.
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Betz, R., Sandhoff, K., Fischer, K.D., and van Echten-Deckert, G. (2003).Luciferase assay
Detection and identification of Vav1 protein in primary cultured murine cere-All cells were grown and transfected as indicated above. For luciferase
bellar neurons and in neuroblastoma cells (SH-SY5Y and Neuro-2a). Neu-reporter assays, 1  106 cells were distributed in triplicate in 24-well plates
rosci. Lett. 339, 37–40.and allowed to recover for 18 hr. The cells were subsequently washed, and
fresh medium containing 1% BCS was added. The cells were then left Billadeau, D.D., Mackie, S.M., Schoon, R.A., and Leibson, P.J. (2000a).
unstimulated or were stimulated with growth factor as indicated. Samples The Rho family guanine nucleotide exchange factor Vav-2 regulates the
were harvested and prepared for luciferase assays according to the protocol development of cell-mediated cytotoxicity. J. Exp. Med. 192, 381–392.
suggested by the manufacturer (Promega, Madison, WI). All reporter assays
Billadeau, D.D., Mackie, S.M., Schoon, R.A., and Leibson, P.J. (2000b).were cotransfected with a pRL-TK reporter plasmid (Promega, Madison, WI)
Specific subdomains of Vav differentially affect T cell and NK cell activation.to control for intersample variations in transfection efficiency. In the latter
J. Immunol. 164, 3971–3981.case, firefly and pRL-TK-derived Renilla luciferase activities were measured
in each sample with a Dual Luciferase Assay Kit (Promega). Bottinger, E.P., Jakubczak, J.L., Roberts, I.S., Mumy, M., Hemmati, P.,
Bagnall, K., Merlino, G., and Wakefield, L.M. (1997). Expression of a domi-
Rho activation and FRET assay nant-negative mutant TGF- type II receptor in transgenic mice reveals
essential roles for TGF- in regulation of growth and differentiation in theCAPAN2 cells (107) were transfected with 30 	g of the indicated suppression
exocrine pancreas. EMBO J. 16, 2621–2633.vectors and 2 	g of a FLAG epitope-tagged Rho family protein expression
vector, and the GTP bound Rho family proteins were determined as de-
Brummelkamp, T., Bernards, R., and Agami, R. (2002). Stable suppression of
scribed in the Supplemental Data at http://www.cancercell.org/cgi/content/ tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243–247.
full/7/1/39/DC1/.
Bustelo, X.R. (2000). Regulatory and signaling properties of the Vav family.
Mol. Cell. Biol. 20, 1461–1477.Chromatin immunoprecipitation assay
PANC1 cells were transfected with full-length Vav1 and control vector. At Bustelo, X.R., Suen, K.L., Leftheris, K., Meyers, C.A., and Barbacid, M.
36 hr posttransfection, cells were crosslinked with formaldehyde for 20 min (1994). Vav cooperates with Ras to transform rodent fibroblasts but is not
at 25C, harvested in SDS-lysis buffer (Upstate Biotechnology, Lake Placid, a Ras GDP/GTP exchange factor. Oncogene 9, 2405–2413.
NY), and sheared to fragment DNA to500 bp. Samples were then immuno-
Cao, Y., Janssen, E.M., Duncan, A.W., Altman, A., Billadeau, D.D., andprecipitated using an agarose-conjugated anti-p65 antibody (Santa Cruz
Abraham, R.T. (2002). Pleiotropic defects in TCR signaling in a Vav-1-nullBiotechnology, Santa Cruz, CA) or agarose beads alone at 4C overnight.
Jurkat T-cell line. EMBO J. 21, 4809–4819.Following immunoprecipitation, samples were washed and eluted using the
Chromatin Immunoprecipitation Kit (Upstate Biotechnology) according to Denkinger, D.J., Borges, C.R., Butler, C.L., Cushman, A.M., and Kawahara,
the manufacturer’s instructions. Crosslinks were removed at 65C for 4 hr, R.S. (2000). Genomic organization and regulation of the vav proto-oncogene.
and immunoprecipitated DNA was purified using phenol/chloroform extrac- Biochim. Biophys. Acta 25, 1–3.
tion (500 	l) and ethanol precipitation. A 200 bp region of the Cylin D1
Doody, G.M., Bell, S.E., Vigorito, E., Clayton, E., McAdam, S., Tooze, R.,promoter was detected in immunoprecipitated samples by PCR. PCR prod-
Fernandez, C., Lee, I.J., and Turner, M. (2001). Signal transduction throughucts were visualized by 2.5% agarose gel.
Vav-2 participates in humoral immune responses and B cell maturation. Nat.
Immunol. 2, 542–547.
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